Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry.

Autor: Schmidt AH; DKMS Group, Tübingen, Germany; DKMS Clinical Trials Unit, Dresden, Germany; DKMS Registry, Tübingen, Germany. Electronic address: schmidt@dkms.de., Sauter J; DKMS Group, Tübingen, Germany., Schetelig J; DKMS Clinical Trials Unit, Dresden, Germany; University Hospital Carl Gustav Carus, Dresden, Germany., Neujahr E; DKMS Group, Tübingen, Germany., Pingel J; DKMS Registry, Tübingen, Germany.
Jazyk: angličtina
Zdroj: Best practice & research. Clinical haematology [Best Pract Res Clin Haematol] 2024 Mar; Vol. 37 (1), pp. 101541. Date of Electronic Publication: 2024 Mar 01.
DOI: 10.1016/j.beha.2024.101541
Abstrakt: Allogeneic hematopoietic stem cell (HSC) transplantation is a curative therapy for many severe blood diseases. As many patients have no suitable family donor, large unrelated donor registries and donor centers have been established in many countries, along with an international system for the provision of unrelated donor HSC products. As an essential part of this system, DKMS operates donor centers in 7 countries with a total of 12.2 million donors and over 114,000 donations so far, and a multinational donor registry. In 2022, DKMS donors contributed 57.5% of all cross-border donations worldwide. In this review, we describe the international system for the provision of unrelated donor HSC products as well as tasks and responsibilities of donor registries and donor centers. We also discuss relevant aspects of DKMS donor centers, namely donor file composition, matching and donation probabilities and actual donations, and the unique multinational approach of the DKMS Registry.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: